AlphaCore Capital’s Moderna MRNA Stock Holding History

AlphaCore Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$499K	Buy	+2,589	New	+$279K	0.01%	830

Other funds holding MRNA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

AlphaCore Capital's MRNA Position: Q3 2026 in Review

AlphaCore Capital opened a new position in Moderna (MRNA) in Q3 2026: 2,589 shares worth $499K. The stake represents 0.01% of the portfolio and ranks #830 among its holdings.

530 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

AlphaCore Capital held 2,589 shares of Moderna worth $499K as of Q3 2026.
Moderna was a new AlphaCore Capital position in Q3 2026.
Moderna made up 0.01% of AlphaCore Capital's portfolio in Q3 2026, its #830 holding.
530 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.